U.S., Oct. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07854769) titled 'Blood Testing to Detect Cancer Recurrence in Patients With Early-Stage Non-Small Cell Lung Cancer' on Sept. 28.
Brief Summary: This observational study will evaluate whether a blood test can detect the return of non-small cell lung cancer at least three months before it is identified on routine imaging. The test measures circulating tumor DNA (ctDNA), which consists of small pieces of DNA released by cancer cells into the blood. Detecting ctDNA after treatment may indicate that cancer cells remain in the body, even when cancer is not visible on scans.
Approximately 200 adults with stage IB-IIIA non-small cell lung cancer who are con...